Krystal Biotech, Inc. (KRYS) Cash flow

Market cap
$10.7B
P/E ratio
2017/122019/122020/122021/122022/122023/122024/12
Depreciation & amortization--234--
Stock-based compensation01315334049
Cash from operations -4-19-26-48-101-89123
Capital expenditures-0-6-15-68-53-12-4
Cash from investing -0-5-11-227-11483-163
Cash from financing 521081183483520327
Free cash flow
FCF margin (%)-----
AI Chat